Doxazosin Tablet
Product Images NDC 68788-8422

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 68788-8422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin Tablets Usp 2mg (E046e0b7 F510 4318 9884 034d683864d4 00)

Label for Doxazosin Tablets USP 2 mg, a prescription oral tablet. The label indicates it is generic for Cardura, manufactured by Apotex Corp. The tablet is white, capsule-shaped, scored, and imprinted with APO 094. Storage instructions note a temperature range of 20°-25°C with permitted excursions. The label includes directions in English and Spanish, as well as warnings and space for lot, batch, expiration, and NDC information.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure diagram of doxazosin, an active pharmaceutical ingredient. The diagram shows molecular bonds and ring structures typical of doxazosin, accompanied by a methanesulfonic acid (CH3SO3H) moiety.*

FDA Label Image

Figure1.jpg (Figure1)

Two line graphs showing clinical data on Doxazosin tablets. The left graph depicts mean change in total symptom score from baseline over 14 weeks, comparing Doxazosin and placebo groups. The right graph shows mean increase in maximum urinary flow rate (mL/sec) from baseline over 14 weeks for the same groups. Doxazosin displays greater improvement in both measures versus placebo.*

FDA Label Image

Table3.jpg (Table3)

A table summarizing effectiveness data from placebo-controlled trials for Doxazosin. It includes symptom score and maximum flow rate measures comparing placebo and Doxazosin at various doses across three studies with patient numbers, baseline means, and mean changes. A bar graph illustrates maximum flow rate and symptom score changes for placebo and Doxazosin 4 mg and 8 mg groups in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.